Literature DB >> 20425536

Intensity of warfarin coagulation in the antiphospholipid syndrome.

Mark Crowther1, Mark A Crowther.   

Abstract

Antiphospholipid syndrome is a condition with an increased propensity for both arterial and venous thrombosis. Compared with the normal population there is also a higher rate of recurrence. Most evidence exists for the use of warfarin in the secondary prevention of thromboembolism, aiming for an international normalized ratio between 2.0 and 3.0. Care must be taken with all anticoagulants because of the increased risk of bleeding. Several other strategies are available if warfarin fails, including the addition of aspirin, increasing the warfarin target range, and use of heparin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425536     DOI: 10.1007/s11926-009-0070-9

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  26 in total

1.  Oral anticoagulation and risk of death: a medical record linkage study.

Authors:  Anders Odén; Martin Fahlén
Journal:  BMJ       Date:  2002-11-09

2.  Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population.

Authors:  W Shi; S A Krilis; B H Chong; S Gordon; C N Chesterman
Journal:  Aust N Z J Med       Date:  1990-06

3.  Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study.

Authors:  A Ruffatti; T Del Ross; M Ciprian; M Nuzzo; M Rampudda; M T Bertero; R Bergia; P Caramaschi; D Biasi; F Capsoni; L Montaguti; R Ruffini; A Brucato; U Picillo; V Fanelli; V Riccieri; A Piccoli; G Valesini; A Doria; P L Meroni; A Tincani
Journal:  Ann Rheum Dis       Date:  2008-09-23       Impact factor: 19.103

Review 4.  Management of antiphospholipid antibody syndrome: a systematic review.

Authors:  Wendy Lim; Mark A Crowther; John W Eikelboom
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

5.  A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).

Authors:  G Finazzi; R Marchioli; V Brancaccio; P Schinco; F Wisloff; J Musial; F Baudo; M Berrettini; S Testa; A D'Angelo; G Tognoni; T Barbui
Journal:  J Thromb Haemost       Date:  2005-05       Impact factor: 5.824

6.  Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.

Authors:  M H Rosove; P M Brewer
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

7.  Incidence of postpartum thrombosis and preterm delivery in women with antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Christine A Clark; Karen A Spitzer; Mark A Crowther; Jamie N Nadler; Matthew D Laskin; Joshua A Waks; Carl A Laskin
Journal:  J Rheumatol       Date:  2007-04-01       Impact factor: 4.666

Review 8.  Current concepts on the pathogenesis of the antiphospholipid syndrome.

Authors:  Bill Giannakopoulos; Freda Passam; Soheila Rahgozar; Steven A Krilis
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

9.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Clive Kearon; Susan R Kahn; Giancarlo Agnelli; Samuel Goldhaber; Gary E Raskob; Anthony J Comerota
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.

Authors:  Steven R Levine; Robin L Brey; Barbara C Tilley; J L P Thompson; Ralph L Sacco; Robert R Sciacca; A Murphy; Yimeng Lu; Teresa M Costigan; Candi Rhine; Bruce Levin; Douglas A Triplett; J P Mohr
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

View more
  1 in total

Review 1.  Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants.

Authors:  Konstantinos N Aronis; Elaine M Hylek
Journal:  J Am Heart Assoc       Date:  2018-01-26       Impact factor: 5.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.